Files in This Item:
   
Thumbnailemhj_2003_9_3_399_406.pdf

View/Open

Title: Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis
Authors: Soliman, A.R.
El Meligi, A.A.
El Semari, M.
El Shemi, M.
Mahmoud, H.
Issue Date: 2003
Language: English
Abstract: Serum transforming growth factor-beta [TGF-beta1] production was estimated for 10 patients with essential hypertension, 12 patients with glomerulonephritis [5 hypertensive and 7 normotensive] and 10 healthy controls. The glomerulonephritis group received angiotensin-converting enzyme inhibitor captopril 25-75 mg/day for 4 weeks. Blood urea, serum creatinine, 24-hour urinary protein and serum TGF-beta1 were then re-estimated. Urea and creatinine were significantly higher in the hypertension and glomerulonephritis groups than in the controls and also higher in the glomerulonephritis group than the hypertension group. TGF-beta1 was significantly higher in the glomerulonephritis groups than in the control and hypertension groups. TGF-beta1 and 24-hour urinary protein were significantly reduced in the glomerulonephritis group
Description: 399-406
Keywords: Blood Urea Nitrogen
Case-Control Studies
Chronic Disease
Creatinine
Glomerulonephritis
Hypertension
Immunoassay
Proteinuria
Subject: Angiotensin-Converting Enzyme Inhibitors
URI: http://www.who.int/iris/handle/10665/119290
ISSN: 1020-3397
Other Identifiers: http://applications.emro.who.int/emhj/0903/emhj_2003_9_3_399_406.pdf
Appears in Collections:EMRO Journal Articles (EMHJ)



Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated.